The efficacy and safety of carbon-ion radiotherapy (CIRT) for locally advanced non- months for all patients and survivors, respectively. Two-year LC, PFS and OS rates were 80.3%, 40.2% and 58.7%, respectively. Overall, 1 (0.7%), 5 (3.5%) and 1 (0.7%) patient developed Grades 4 (mediastinal hemorrhage), 3 (radiation pneumonitis) and 3 (bronchial fistula) toxicities, respectively. Multivariate analysis showed adenocarcinoma and N2/3 classification as significant poor prognosticators of PFS. CIRT is an effective treatment with acceptable toxicity for LA-NSCLC, especially for elderly patients or patients with severe comorbidities who cannot be treated with surgery or chemoradiotherapy.
K E Y W O R D S
carbon-ion radiotherapy, effectiveness, elderly patients, locally advanced non-small-cell lung cancer, radiation therapy several studies, platinum-based concurrent chemoradiotherapy was performed for patients with LA-NSCLC, and the 2-year high overall survival (OS) rate was approximately 50%-60%. [3] [4] [5] However, in contrast to its survival benefit, concurrent chemoradiotherapy induces severe hematologic toxicity, infection, esophagitis and pneumonitis; therefore, chemoradiotherapy is sometimes a heavy burden in elderly patients or patients with severe comorbidities. [6] [7] [8] As an alternative treatment option, radiotherapy alone or low-dose carboplatin-based concurrent chemotherapy is sometimes introduced to patients, but such patients have a 2-year OS rate of approximately 5%-40%, with a poor prognosis. 9, 10 Carbon-ion radiotherapy (CIRT) is a high linear energy transfer radiotherapy that is being widely used across Europe and Asia. CIRT has good dose-localizing properties. 11 Therefore, it can deliver a higher dose to the target volume than conventional photon radiotherapy while avoiding the adjacent critical organs at risk, such as the lung, esophagus, trachea and heart. In fact, CIRT can clinically achieve high local control (LC) rates with low toxicity. CIRT may be a promising treatment option for LA-NSCLC.
However, the efficacy and safety of CIRT are not clearly understood, with only 2 published studies having reported on a small number of patients with LA-NSCLC. 12, 13 In this study, we retrospectively analyzed the clinical outcomes in 141 patients treated for LA-NSCLC with CIRT.
| MATERIAL S AND ME THODS

| Study design
This study was approved by the Institutional Review Board of our institution. Research was conducted in accordance with the Helsinki Declaration. This study was a retrospective evaluation of 141 patients from a previously reported prospective phase Ι/ΙΙ study of 72 patients and a retrospective study of 69 patients who were deemed ineligible for the phase Ι/ΙΙ study at our institution. The details of the prospective phase Ι/ΙΙ study were previously reported.
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The eligibility criteria for this study conducted between June 1995
and November 2015 at our institution were as follows: (i) histologi- 
| Carbon-ion radiotherapy
Patients were fixed using an individually tailored immobilization device (Moldcare; Alcare, Tokyo, Japan; Shellfitter; Kuraray, Osaka, Japan), and CT images were taken in the supine or prone position using respiratory sensors to monitor the respiratory phase. 12, 13 Primary lung lesion and metastatic lymph nodes were contoured dose escalation study was conducted in the cradle of our study and has been previously reported. 12 Consequently, the recommended dose was fixed at 72 Gy (RBE) in 16 fractions. Subsequently, this dose was adopted for all patients (n = 89, 63.1%). The total dose was applied to the isocenter, and it enclosed the PTV conformably, with the 95% isodose line. With lymph node metastasis, prophylactic lymph nodes were irradiated at a median dose of 49.5 Gy (RBE).
12,18
The following irradiation dose constraints were applied: main bron- 
| Follow-up
After treatment, follow-up observations were performed at 1, 3, 6, 9 and 12 months, and every 3-6 months after 12 months if serious complications had not occurred. During each follow-up observation, chest CT, chest X-ray and a blood test were performed. If necessary, brain magnetic resonance imaging or positron emission tomography (PET) was performed.
| Statistical analyses
Local control, locoregional control (LRC), progression-free survival (PFS) and OS were calculated using the Kaplan-Meier method. LC was defined as the time interval between irradiation commencement date and the local tumor regrowth in the PTV date or the last follow-up. LRC was defined as the time interval between the irradiation commencement date and the local or regional relapse date or the last follow-up. PFS was defined as the time interval between the irradiation commencement date and the date of disease progression at any site, death from any cause, or the last follow-up. OS was defined as the time interval between the irradiation commencement date and death, or the last follow-up.
To determine the prognostic factors of PFS and OS, univariate analysis was performed using the log-rank test. The patients were divided into subgroups according to the median values of age, total dose, the CTV, and the CIRT treatment timing (before or after January 2005). Multivariate analysis was performed using the Cox proportional hazards model. A 2-tailed P < .05 was considered statistically significant. All statistical analyses were conducted using JMP statistical software (version 14.0; SAS Institute, Cary, NC, USA).
| RE SULTS
| Patient characteristics
Two patients discontinued CIRT at 67. 
| Local control and survival
By the end of follow-up, 58 and 49 patients had either died of cancer or unrelated causes, while 34 patients survived. At the time of first relapse, 14 local recurrences, 32 regional recurrences (regional lymph nodes or/and satellite nodes in the ipsilateral lung) and 47 distant metastases were detected.
| Toxicities
In total, 1 (.7%) patient developed Grade 4 mediastinal hemorrhage, 5 (3.5%) developed Grade 3 radiation pneumonitis and 1 (.7%) developed Grade 3 bronchial fistula ( Table 2 ).
The patient with Grade 4 mediastinal hemorrhage was diagnosed with locally advanced lung cancer (ycT4N2M0, Stage IIIB). T4
classification was diagnosed as an invasion to the mediastinum. The We focused on the elderly patients older than 70 years (Table   S1 ); 4 (4.4%) developed Grade 3 radiation pneumonitis and 1 (1.1%) developed Grade 3 bronchial fistula.
| Prognostic factors
Univariate and multivariate analyses were performed to identify potential prognostic factors of PFS and OS among the different subgroups (Table 3) . On the basis of the significant P-values from the univariate analysis, multivariate analysis was performed. The results revealed that N classification (P = .009) and histology (P < .001) were significant predictors of PFS and that the timing of CIRT (P = .012) was a significant predictor of OS (Table 4) . Furthermore, the 2-year PFS rates of N0-1 vs N2-3 patients were 44.8% vs 29.3% (Figure 2A ).
The 2-year PFS rates of patients with adenocarcinoma vs the other histology were 23.6% vs 53.5% ( Figure 2B ).
Associations between stage and outcomes were also evaluated.
Although no significant difference was identified, 2-year PFS and OS rate of stages ΙΙ or ΙΙΙ were 40.0% and 61.8% or 40.6% and 54.9%, respectively. TA B L E 3 (Continued) such as CIRT, are required for more effective and safe treatment. To date, only 2 studies of relatively small numbers of patients in terms of CIRT for LA-NSCLC have been published. 12, 13 To the best of our knowledge, our study has reported the largest number of patients in evaluating the efficacy and toxicity of CIRT in LA-NSCLC. Our findings demonstrated that CIRT is effective and has an acceptable toxicity and that CIRT has become the reasonable treatment option, especially for elderly patients or patients with severe comorbidities who cannot be treated with surgery or chemoradiotherapy.
| D ISCUSS I ON
Bradley et al. 4 performed the Radiation Therapy Oncology Group 0617 trial of photon chemoradiotherapy for stage ΙΙΙ LA-NSCLC and showed that the median PFS, median OS, 2-year PFS and OS rates in patients who received 60 Gy irradiation plus concurrent chemotherapy were 11.8 months, 28.7 months, 30.7% and 57.6%, respectively.
Yamamoto et al. 5 conducted a multicenter phase ΙΙΙ trial of photon chemoradiotherapy for stage ΙΙΙ LA-NSCLC. They showed that median PFS and median OS of patients who received cisplatin plus paclitaxel chemoradiotherapy were 9.5 and 22.0 months, respectively.
Meanwhile, using CIRT, Takahashi et al. and Karube et al. treated 62 and 64 patients with stages ΙΙ/ΙΙΙ LA-NSCLC, respectively. 12, 13 They illustrated that the 2-year PFS and OS rates were 42.3% and 51.9%-62.2%, respectively. The present study revealed that the median PFS, median OS, 2-year PFS and OS for stages ΙΙ/ΙΙΙ LA-NSCLC were 11.6 months, 29.3 months, 40.2% and 58.7%, respectively. By grouping their patients into stages ΙΙ or ΙΙΙ, the corresponding values for patients with stage ΙΙΙ were 10.1 months, 27.6 months, 40.6%
and 54.9%, respectively. These findings may indicate that CIRT is approximately comparable to photon chemoradiotherapy.
In the present study, 1 (.7%) patient developed Grade 4 mediastinal hemorrhage from the aortic arch, to which the primary tumor was very close. This patient had received bevacizumab for 3 months before CIRT. Spigel et al. 19 reported that photon chemoradiotherapy, including bevacizumab, was associated with a relatively high incidence of tracheoesophageal fistulae formation in patients with primary lung cancer. The authors hypothesized that bevacizumab, an angiogenesis inhibitor, delays the healing of antecedent mucosal injury from chemoradiotherapy, leading to severe tracheoesophageal mucosal injury. This hypothesis may be applicable to our Grade 4 mediastinal hemorrhage case. Considering that the wall of the aortic arch, which was irradiated within the high dose area, was injured, bevacizumab delayed the healing of the wall injury. Consequently, a false aneurysm, which developed around the aortic arch, was ruptured. In addition, the other study reported that bevacizumab and high dose re-irradiation with CIRT to the trachea might increase the risk of tracheal necrosis. 20 These results suggest a warning about the increased risk of rupture with bevacizumab and high dose irradiation with CIRT to the great vessel. We treated the other 4 patients who received adjuvant chemotherapy including bevacizumab, and, fortunately, no great vessel toxicity occurred.
Regarding severe toxicity, hematologic toxicity is the most frequent in photon chemoradiotherapy for LA-NSCLC; in contrast, concerning non-hematologic toxicity, radiation pneumonitis and esophagitis are generally considered as major risks. 4 Some studies have shown, using photon chemoradiotherapy, that Grade ≥3
pneumonitis and esophagitis were .7%-11% and 7%-20%, respectively. 4, 5, 21 Meanwhile, our study using CIRT showed that Grade 3 radiation pneumonitis was observed in only 3.5% of all patients.
None of our patients developed Grade ≥3 esophagitis or any hematologic toxicity. Our findings suggest that, with respect to Grade ≥3 toxicity, CIRT is superior to photon chemoradiotherapy.
Concerning the standard treatment for the elderly patients with LA-NSCLC, whether chemotherapy should be added to radiotherapy or not is controversial. 8 Some studies reported an improvement in survival with the addition of chemotherapy to radiation but they also had an increase in severe toxicity. 9, 22, 23 In fact, Atagi et al. 9 conducted a randomized, controlled, phase 3 trial using radiotherapy with or without low-dose carboplatin in elderly patients (>70 years old) with stage ΙΙΙ LA-NSCLC. The median PFS and OS for chemoradiotherapy or radiotherapy alone groups were 8.9 and 22.4 months, or 6.8 and 16.9 months, respectively.
As expected, patients in the chemoradiotherapy group suffered more Grade 3 to 4 hematologic toxicity and Grade 3 infections than those in the radiotherapy alone group. As expected, the for- CIRT is approximately comparable in efficacy to photon concurrent chemoradiotherapy in elderly patients but with less toxicity.
Recently, the risk factors, including the lung volume receiving ≥30 Gy (RBE) for Grade ≥2 radiation pneumonitis after CIRT, were reported. 18 In future, we may be able to reduce the incidence of severe radiation pneumonitis as risk factors.
In the multivariate analysis, we found that N2-3 classification (P = .009) and adenocarcinoma (P < .001) were significant poor prognostic factors of PFS. This may have arisen from the fact that these factors often cause regional lymph nodes outside the irradiated field, or distant metastasis. In addition, OS in patients who were treated in the earlier part of the timing of CIRT (i.e. before January 2005) were significantly poor (P = .012) compared to those whose timing occurred later. The reason for this is not clear; however, this may have arisen due to the lack of PET-CT for disease staging. From 2005, almost all patients with LA-NSCLC had PET-CT done, and consequently, we were able to assess for distant metastasis and metastatic lymph nodes more accurately. 24 Our study had several limitations. First, our study is a single-center retrospective analysis. Second, our results might have underestimated the late toxicity because the median follow-up duration (29.3 months) of all 141 patients was not sufficient. Finally, the total doses and fractionation varied (54-76 Gy (RBE) in 12-16 fractions). Therefore, further large-scale multicenter prospective trials are warranted.
In conclusion, CIRT is an effective treatment option with acceptable toxicity for LA-NSCLC, especially for elderly patients or patients with severe comorbidities who cannot be treated with surgery or chemoradiotherapy. CIRT demonstrated comparable efficacy to photon chemoradiotherapy but with less toxicity.
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